

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2020/167918 A8

(43) International Publication Date
20 August 2020 (20.08.2020)

(51) International Patent Classification:

C07K 14/705 (2006.01) *G01N 33/58* (2006.01)
C12Q 1/6876 (2018.01)

(21) International Application Number:

PCT/US2020/017887

(22) International Filing Date:

12 February 2020 (12.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/804,649	12 February 2019 (12.02.2019)	US
62/826,823	29 March 2019 (29.03.2019)	US
62/867,165	26 June 2019 (26.06.2019)	US
62/876,380	19 July 2019 (19.07.2019)	US

(71) Applicant: **PACT PHARMA, INC.** [US/US]; 2 Corporate Drive, South San Francisco, CA 94080 (US).

(72) Inventors: **PENG, Songming**; C/o Pact Pharma, Inc., 2 Corporate Drive, South San Francisco, CA 94080 (US). **QUACH, Boi, Bryant**; C/o Pact Pharma, Inc., 2 Corporate Drive, South San Francisco, CA 94080 (US). **AN, Duo**; C/o Pact Pharma, Inc., 2 Corporate Drive, South San Francisco, CA 94080 (US). **BAO, Xiaoyan, Robert**; C/o Pact Pharma, Inc., 2 Corporate Drive, South San Francisco, CA 94080 (US). **FRANZUSOFF, Alexis**; C/o Pact Pharma, Inc., 2 Corporate Drive, South San Francisco, CA 94080 (US). **SENNINO, Barbara**; C/o Pact Pharma, Inc., 2 Corporate Drive, South San Francisco, CA 94080 (US). **DALMAS, Olivier**; C/o Pact Pharma, Inc., 2 Corporate Drive, South San Francisco, CA 94080 (US). **MANDL-CASHMAN, Stefanie**; C/o Pact Pharma, Inc., 2 Corporate Drive, South San Francisco, CA 94080 (US).

(54) Title: COMPOSITIONS AND METHODS FOR IDENTIFICATION OF ANTIGEN SPECIFIC T CELLS




FIG. 62

(57) Abstract: Disclosed herein are antigenic peptide-MHC complexes, termed comPACT polypeptides and comPACT polynucleotides, and methods of producing such complexes. Also discloses herein are methods of producing libraries of comPACT polynucleotides and polypeptides, and their exemplary use in capturing cancer neoepitope-reactive T cells with high accuracy. Dual particle detection approaches for detection of neoantigen specific T cells with improved sensitivity and specificity are provided. Signal to noise ratio analysis of isolated T cells for detection of neoantigen-specific T cells with improved T cells is also provided.

[Continued on next page]

(74) **Agent: LENDARIS, Steven, P.** et al.; Baker Botts LLP, 30 Rockefeller Plaza, New York, NY 10112-4498 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) **Date of publication of this corrected version:**
17 September 2020 (17.09.2020)

(15) **Information about Correction:**
see Notice of 17 September 2020 (17.09.2020)